Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That "news" about Advaxis is three months old.
Agree. Management could have done more to keep shareholders aware of the situation. DOC had a blog, at one time, I believe and had promised to post to keep shareholders aware of progress. I still believe, if not for the unnecessary hold, we would be much further along and, I also believe, at a higher PPS. I think now we'll see some good upward movement.
"Not good - no real progress to show" Wow, you're right. After all, you certainly can't call the PIII progress...
"Nicole Ehrhart is a professor of veterinary medicine at Colorado State University. She receives funding from The Limb Preservation Foundation, Aratana Therapeutics and Allosource Inc. She serves as a consultant for Aratana Therapeutics, which funded the work (not in her laboratory) using immunotherapy in dogs with osteosarcoma."
Well, imagine my surprise, "...and is in Phase III clinical trials for three potential indications: invasive cervical cancer, head and neck cancer, and anal cancer."
Their other trials don't seem to be affected so maybe not.
So, the company eventually has to pay the money back. I remember that from somewhere but forgot about that point.
At least Biocon is still on the tab.
I find it odd, though, that Stendhal does not appear on the "Collaborations" tab which seems to have everyone else.
So long, Schwartz...
"We're going to streamline the FDA. We have a fantastic person that I think I will be naming very soon. We're going to streamline the FDA. You're going to get your products either approved or not approved but it's going to be a quick process. It's not going to take 15 years. I read where it sometimes takes $2.5 billion on average to come up with a new products. 15 years, $2.5 billion to come up with a new product where there is not even a safety problem. That's crazy." This bodes well for Advaxis. Amgen was at the meeting, also. Maybe change protocol to allow more companies to get approved after PI and PII trials, with a confirmatory trial, after? Or, more AA's?
Don't know if this was already posted but it's a good read. You can search for DCVax-L but I recommend reading the whole article.
http://ar.iiarjournals.org/content/37/1/21.full
Ig, you can just google Twitter on your PC and, once you're on the site, you can search by the doctor's (or anybody's) name.
Under upcoming milestones, the corporate presentation states, "Preliminary data from ADXS-PSA + pembrolizumab cohorts A + B (2017)". ASCO, or maybe before?
Maybe the "new hope" he mentions applies to the Advaxis approach.
I'm not sure sending an email to Advaxis would do any good. They rarely mention AT-014. Aratana, one would think, would be pouring more effort into getting this approved as this could become the SOC. Your email is as good as mine. Go for it.
Great post, RK! Thanks.
The way Trump is signing executive orders to lessen energy and environmental restrictions, I hope to see some regarding the FDA processes. That could only help Advaxis.
Well, if it had that effect, I'm very happy. I'm sure fellow investors chimed in. At least the company is not turning a deaf ear to us.
Here's an email I sent to Ranya on 1/9. I'm not saying that my email had anything to do with all the updates on 1/18 to the clinicaltrial.gov page but I did post on 1/13 here that I sent an email asking for site updates and I felt that, if more people emailed asking for updates it may help. Well, look at the sites section now.
Dear Ranya,
Congratulations to the Company on their recent business update. The year looks to be pivotal in the Company's success. If I may make a small suggestion, please keep the clinicaltrials.gov page updated as new sites come on-line. I would like every possible patient to see where they may participate in our clinical trials. The business update states, "There are 10 active trial sites in the United States as of this week." for the AIM2CERV trial but clinicaltrials. gov shows only 2 up running. It is psychologically comforting to see the success at adding new sites and, I believe, helps keep resolve to investors.
Again, I have a strong belief in this Company and it's science and I look forward to a future where our treatments help ease the suffering of cancer patients everywhere.
Sincerely,
Actually, it was 55.6% in 69% of the patients given all 3 doses. So, why don't we have a breakthrough designation?
This sentence from the corporate presentation still makes me laugh, "Proven leadership with record of creating shareholder value." Given that the incompetent management of this company can't seem to do anything right, I suppose it is possible that the Zoptrex trial could be successful in spite of them. I have a few options I bought on a whim. Given the low float and lack of a approved treatment for this indication if, and that's a big if, the trial has good results what would be a REASONABLE price for the stock?
I remember someone on the old YMB said they talked a friend or co-worker into going "all in" on this stock. I'm sure they're BBF's now. We'll know soon enough if the company is destined for failure or they get a reprieve from ignominy.
I would think Aduro would have PR'd it if they had an approved IND for NEO. I haven't seen one yet.
Advaxis and Compugen both have Antoni Bibas on their SAB.
Good interview. She must have seen some things she liked before jumping ship.
Seems to be the way of the future. Combo treatments. Eventually, a combination will be configured that will knock cancer on it's ass. I want Advaxis to be in the forefront for that. I have a few bucks here and there also on small bios with combo trials.
I'm not holding out for anything big in the next month or two but we should get a PIII AIM2CERV enrollment update at ASCO, IND for NEO by midyear, possible canine vaccine approval and pediatric osteosarcoma study start.
Dr. Wilson in some good company here.
http://www.immunotherapyforum.com/speakers?&azletter=G&searchgroup=C74FA377-speakers-hjjh
Amen! We are of a like mind.
I've emailed Hans, Greg and now Ranja about this. The clinicaltrials.gov needs updating. There are many more sites open for the AIM2CERV trial than what shows on the clinicaltrials.gov page. I can't imagine it takes a lot of work to keep these pages current. What's the point of having these sites open if patients can't find them? Maybe, if enough of us contact IR, they'll take it seriously.
Bomba, that was great!
I don't have time to look for it though some of the other posters may remember where and when it was said. I think it was shortly after he was hired.
Agreed!
I think it was DOC stating where the stock would be (550) in a few years and the RSU grab. Once you make a statement like that, it will haunt you forever. Are we better off now than before DOC took over? Absolutely. If DOC had not made that earlier statement, I think more investors would be content at the progress to date.
Looks like they're either combining some trials or cutting back to save resources. Don't see the NSCLC trial or the TNBC trial on the timeline. The TNBC could be one that's rolled into the HER2 trial.
Here's the link to presenting companies. Many of the usual suspects are there but Advaxis is not on the list.
http://www.ebdgroup.com/bts/core/presenting-companies.php?_ga=1.63948399.1522662026.1483982850
I'm not holding out for too much revenue from AT-014 but it's likely that it will be our first commercialized product and that is an advantage over other bios.
How do you know?
Two new job openings this week. Associate Director, Clinical Operations and Associate Director, Medical Science Liaison.